Assiya Kussainova

Dr. Assiya Kussainova


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
YSYuliya Semenova
Yuliya Semenova
LKLaura Kassym
Laura Kassym
AKAssiya Kussainova
Assiya Kussainova
AAAinur Aimurziyeva
Ainur Aimurziyeva
LMLarissa Makalkina
Larissa Makalkina
LLLisa Lim
Lisa Lim
During the COVID-19 pandemic, a ban on inspections of small businesses, including pharmacies, was imposed in Kazakhstan, which relaxed law enforcement efforts regarding the prohibition of over-the-counter antibiotic (AB) sales. This study aimed to investigate how this affected the knowledge, attitudes, and practices (KAP) related to AB and antimicrobial resistance (AMR), as well as to assess actual AB consumption at the community level. The study comprised two cross-sectional sub-studies: the first involved a KAP survey conducted in 2022 and 2024, utilizing the Special Eurobarometer questionnaire on AMR. The second sub-study analyzed AB consumption in 2021 and 2023, measured in defined daily doses per 1000 inhabitants. Results revealed an increase in the percentage of individuals reporting receipt of information about ABs and AMR in the past year (37.3% in 2022 vs. 52.9% in 2024, p < 0.001) and an increase in the percentage of individuals reporting AB use in the past year (49.0% in 2022 vs. 54.0% in 2024, p = 0.056). The most consumed ABs were from the Watch group, with azithromycin and ceftriaxone ranking highest. These findings support the hypothesis that the relaxation of law enforcement contributed to an increase in AB consumption and emphasize the need for public health policies to address this issue.

27 April 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LKLaura Kassym
Laura Kassym
AKAssiya Kussainova
Assiya Kussainova
YSYuliya Semenova
Yuliya Semenova
PMPauline McLoone
Pauline McLoone
Growing concern over antimicrobial resistance in chronic wound patients necessitates the exploration of alternative treatments from natural sources. This study suggests that honey’s phenolic compounds may offer antimicrobial benefits, warranting further investigation for therapeutic development. The main aim of this study was to investigate the antimicrobial activity of phenolic compounds and to determine the effects of their sub-inhibitory concentrations against Escherichia coli (E. coli). 3-phenyllactic acid (PLA), p-coumaric acid (PCA), and phloretin were tested against the bacterial strain of E. coli ATCC 25922. Comparison of the antimicrobial activity of honey constituents in vitro was performed using a broth culture assay. Measurement of the inhibitory properties of constituents in vitro was conducted using disc and well diffusion assays. The effects of sub-inhibitory concentrations of PCA on the susceptibility of E. coli ATCC 25922 to penicillin–streptomycin were tested. The results demonstrated that PLA was the most efficient antimicrobial agent, followed by PCA, whereas phloretin, at lower (2 mg/mL) concentrations, led to an increase in the growth of E. coli. Various modifications of the agar diffusion assay did not reveal the antibacterial properties of the studied phytochemicals. The enhancing effect of a sub-inhibitory concentration of PCA in cooperation with penicillin–streptomycin was shown. These findings might be helpful for the further investigation and development of new antimicrobial agents for the treatment of skin infections and wounds.

21 February 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LKLaura Kassym
Laura Kassym
AKAssiya Kussainova
Assiya Kussainova
DSDaniil Semenov
Daniil Semenov
AAAinur Aimurziyeva
Ainur Aimurziyeva
SUSaltanat Uzbekova
Saltanat Uzbekova
YSYuliya Semenova
Yuliya Semenova
Antibiotic resistance (AMR) has reached critical levels globally, especially in developing economies like Kazakhstan, largely due to improper antibiotic use. The aim of this study was to examine seven years of azithromycin sales data in Kazakhstan to uncover consumption patterns during the COVID-19 pandemic and develop effective strategies to combat AMR. This study analyzes two data sets: one from a comprehensive review of documents regulating azithromycin use in Kazakhstan. The second data set consists of a pharmaco-epidemiological analysis of azithromycin consumption from procurement data provided by Vi-ORTIS. Azithromycin consumption (ATC group J01FA10) from 2017 to 2023 was measured in DDD/1000 inhabitants/day (DID) using the ATC/DDD methodology. Azithromycin is extensively used in adult and pediatric care in Kazakhstan. Its consumption, measured in DDD per 1,000 inhabitants, surged in 2020 with the COVID-19 outbreak. The steady annual increase in “Watch” antibiotics, including azithromycin, should alarm Kazakhstan’s healthcare system. This trend highlights the need for stronger stewardship programs, targeted interventions, and comprehensive monitoring to prevent antibiotic overuse and misuse. Addressing this is crucial to maintaining antibiotic effectiveness and safeguarding public health.

6 September 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
YSYuliya Semenova
Yuliya Semenova
AKAssiya Kussainova
Assiya Kussainova
LKLaura Kassym
Laura Kassym
AAAinur Aimurziyeva
Ainur Aimurziyeva
DSDaniil Semenov
Daniil Semenov
LLLisa Lim
Lisa Lim
Background/Objectives: While multiple studies have investigated antibiotic consumption rates, there are few studies on the consumption of systemic antifungals and antiprotozoals. This study aims to fill this gap by providing a comprehensive analysis of nationwide consumption trends in Kazakhstan over a seven-year period (2017–2023). Methods: Defined daily doses per 1000 inhabitants per day were calculated for systemic antifungals (J02 code of the Anatomical Therapeutic Chemical Classification System (ATC)) and antiprotozoals (P01 code of the ATC). Time series analyses were applied to examine historical trends, evaluate the impact of the COVID-19 pandemic, and make future projections until 2030. Results: The total consumption increased over the study period, with an average annual percent change of 1.11% for antifungals and 5.48% for antiprotozoals. Fluconazole was the most consumed antifungal agent, whereas metronidazole was the most consumed antiprotozoal agent. The COVID-19 pandemic had a positive but insignificant effect on the consumption of antifungals and a negative and also insignificant effect on the consumption of antiprotozoals. Forecast modeling indicates that the future trends in antifungal and antiprotozoal consumption until 2030 will largely remain stable, with the exception of antiprotozoal consumption in the hospital sector, which is projected to decline. Conclusions: These findings offer valuable insights into the development and implementation of targeted antimicrobial stewardship programs in Kazakhstan.